Hanmi lands up to $2.3bn Genentech deal as non-incretin obesity drug HM17321 reaches its first human test
Genentech has licensed HM17321 outside South Korea for $190 million upfront and up to about $2.3 billion in total potential payments, betting on a UCN2 mechanism designed to reduce fat while preserving lean mass.